Skip to main content
SpringerLink
Log in

Follow-up of Oncology Patients Undergoing Chemotherapy

  • Chapter
Enhancing the Role of Ultrasound with Contrast Agents

Conclusion

Many new functional imaging techniques, with their strengths, weaknesses and costs, are expected to reach the clinic for early assessment of tumour response to new drugs in development. These allow an evaluation of the efficacy of innovative treatments in oncology, such as the anti-angiogenic and anti-vascular treatments that are in full expansion and are aimed at the destruction of tumour vascularisation.

In ultrasonography, the combination of perfusion software and contrast agents gives rise to a functional imaging method. The access to raw data and the development of software using the tracking of lesions permits a more precise and objective quantification of treatment efficiency to be performed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Folkman J (1971) Tumour angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186

    Article  PubMed  CAS  Google Scholar 

  2. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27

    Article  PubMed  CAS  Google Scholar 

  3. Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH (2005) Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 97:172–187

    Article  PubMed  CAS  Google Scholar 

  4. Rehman S, Jayson G (2005) Molecular Imaging of antiangiogenic agents. The Oncologist 10:92–103

    Article  PubMed  CAS  Google Scholar 

  5. World Health Organisation Offset Publication, editor (1979) WHO Handbook for Reporting Results of Cancer Treatment Geneva (Switzerland)

    Google Scholar 

  6. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216

    Article  PubMed  CAS  Google Scholar 

  7. Schwartz L (2004) Conventional and novel techniques for therapeutic response assessment. Radiological Society North America (RSNA). 90th Scientific Assembly and Annual Meeting, Chicago. Proc Radiology 115

    Google Scholar 

  8. Cosgrove D (2003) Angiogenesis imaging. Ultrasound. the British Journal of Radiology 76:S43–S49

    Article  PubMed  Google Scholar 

  9. Lassau N, Paturel-Asselin C, Guinebretiè JM et al (1999) New haemodynamic approach to angiogenesis: colour and pulsed Doppler ultrasonography. Invest Radiol 34:194–198

    Article  PubMed  CAS  Google Scholar 

  10. Asselin C, Lassau N, Guinebretiè JM et al (1999) The in vivo murineinterleukin-12 transfer by the Semliki Forest Virus induces B16 tumour regression through inhibition of tumour blood vessel formation monitored by Doppler ultrasonography. Gene Therapy 4:606–615

    Article  CAS  Google Scholar 

  11. Escudier B, Lassau N, Couanet D et al (2002) Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 13(7):1029–1035

    Article  PubMed  CAS  Google Scholar 

  12. Hochedez P, Lassau N, Bonvalot S et al (2003) Treatment of local recurrent melanomas by isolated limb perfusion: value of Doppler ultrasonography. J Radiol 84(5):597–603

    PubMed  CAS  Google Scholar 

  13. Lassau N, Koscielny S, Opolon P et al (2001) Evaluation of contrast-enhanced colour Doppler ultrasound for the quantification of angiogenenis in vivo. Invest Radiol 36:50–55

    Article  PubMed  CAS  Google Scholar 

  14. Lassau N, Lamuraglia M, Leclere J, Rouffiac V (2004) Functional and early evaluation of treatments in oncology: interest of ultrasonographic contrast agents. J Radiol 85(5):704–712

    PubMed  CAS  Google Scholar 

  15. Eggermont AM (2005) Evolving imaging technology: contrast-enhanced Doppler ultrasound is early and rapid predictor of tumour response. Ann Oncol 16(7):995–996

    Article  PubMed  CAS  Google Scholar 

  16. Lassau N, Lamuraglia M, Vanel D et al (2005) Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Ann Oncol 16(7):1054–1060

    Article  PubMed  CAS  Google Scholar 

  17. Lassau N, Chawi I, Rouffiac V et al (2004) Interest of colour Doppler ultrasonography to evaluate a new anti-angiogenic treatment with thalidomide in metastatic renal cell carcinoma. Bull Cancer 91(7–8):629–635

    PubMed  Google Scholar 

  18. Hsu C, Chen CN, Chen LT et al (2005) Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors. Radiology 235(2):509–516

    PubMed  Google Scholar 

  19. Connolly EM, Gaffney E, Reynolds JV (2003) Gastrointestinal stromal tumours. Br J Surg 90:1178–1186

    Article  PubMed  CAS  Google Scholar 

  20. Berman J, O’Leary TJ (2001) Gastrointestinal stromal tumor workshop. Hum Pathol 32:578–582

    Article  PubMed  CAS  Google Scholar 

  21. Emory TS, Sobin LH, Lukes L et al (1999) Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 23:82–87

    Article  PubMed  CAS  Google Scholar 

  22. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052

    Article  PubMed  CAS  Google Scholar 

  23. van Oosterom AT, Judson I, Verweij J et al (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358:1421–1423

    Article  PubMed  Google Scholar 

  24. van Oosterom AT, Judson IR, Verweij J et al (2002) Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38[Suppl 5]:S83–S87

    Article  PubMed  Google Scholar 

  25. Verweij J, van Oosterom A, Blay JY et al (2003) Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39:2006–2011

    Article  PubMed  CAS  Google Scholar 

  26. Savage DG, Antman KH (2002) Imatinib mesylate-a new oral targeted therapy. N Engl J Med 346:683–693

    Article  PubMed  CAS  Google Scholar 

  27. Chen MY, Bechtold RE, Savage PD (2002) Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). AJR Am J Roentgenol 179:1059–1062

    PubMed  Google Scholar 

  28. Lassau N, Lamuraglia M, Chami L et al (2005) Gastro-intestinal stromal tumours treated with Imatinib: Monitoring response with contrastenhanced ultrasound. AJR (in press)

    Google Scholar 

  29. Hotta N, Tagaya T, Maeno T et al (2005) Advanced dynamic flow imaging with contrast-enhanced ultrasonography for the evaluation of tumour vascularity in liver tumours. Clin Imaging 29: 34–41

    Article  PubMed  Google Scholar 

  30. Shankar S, vanSonnenberg E, Desai J et al (2005) Gastri-intestinal stromal tumour: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 235(3):892–898

    PubMed  Google Scholar 

  31. Lassau N, Lamuraglia M, Chami L et al (2005) Doppler-ultrasonography with perfusion software and contrast agent injection as an early evaluation tool of metastatic renal cancers treated with the Raf-Kinase and VEGFR inhibitor: a prospective study. J Clinic Onco 3[Suppl 16]:209. ASCO Annual Meeting Proceedings

    Google Scholar 

  32. Wilhelm S, Chien DS (2002) BAY 43-9006: preclinical data. Curr Pharm Des 8(25):2255–2257

    Article  PubMed  CAS  Google Scholar 

  33. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis. Cancer Res 64(19):7099–7109

    Article  PubMed  CAS  Google Scholar 

  34. Sridhar SS, Hedley D, Siu LL (2005) Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 4(4):677–685

    Article  PubMed  CAS  Google Scholar 

  35. Rini BI, Weinberg V, Shaw V et al (2004) Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma. Cancer 101(1):90–95

    Article  PubMed  CAS  Google Scholar 

  36. Mazumdar M, Smith A, Debroy P, Schwartz L (2005) A theorical approach to choosing the minimum number of multiple tumors required for assessing treatment response. J Clin Epidemiol 58:150–153

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ultrasonography Unit and Imaging Laboratory of Small Animal, Imaging Department, Institut Gustave-Roussy, Villejuif, France

    Nathalie Lassau

  2. Ultrasonography Unit, Imaging Department, Institut Gustave-Roussy, Villejuif, France

    Jérome Leclère

  3. Imaging Laboratory of Small Animal, Imaging Department, Institut Gustave-Roussy, Villejuif, France

    Pierre Péronneau

Authors
  1. Nathalie Lassau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jérome Leclère
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pierre Péronneau
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Diagnostic and Interventional Radiology, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Pisa, Italy

    Riccardo Lencioni

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Italia

About this chapter

Cite this chapter

Lassau, N., Leclère, J., Péronneau, P. (2006). Follow-up of Oncology Patients Undergoing Chemotherapy. In: Lencioni, R. (eds) Enhancing the Role of Ultrasound with Contrast Agents. Springer, Milano. https://doi.org/10.1007/88-470-0476-4_6

Download citation

  • DOI: https://doi.org/10.1007/88-470-0476-4_6

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-0475-7

  • Online ISBN: 978-88-470-0476-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation